The oral converting-enzyme inhibitor captopril shows promise in the treatment of cardiac failure. We used the drug in five patients with congestive heart failure that had proved unresponsive to conventional treatment and observed a clear-cut fall in plasma sodium concentration.
Methods and results
We studied five men aged 54-72 years with congestive heart failure (New York Heart Association functional class III or IV) secondary to coronary artery disease. All had previously received conventional medications, including vasodilators, without success. Throughout the seven-day study they received a constant dietary intake of sodium (33-48 mmol(mEq)/day) and potassium (73-100 mmol(mEq)/day; body posture was restricted to the supine and sitting positions in bed; and their regular doses of digoxin (62-5-250 ,ug/day) and frusemide (80-500 mg/day) were continued. All other drugs were stopped at least five days before the study. After a two-day run-in period captopril was administered by mouth in an eight-hourly incremental regimen (6-25-150 mg/dose), and blood was drawn one hour after each dose increase for measurement of plasma electrolyte and hormone concentrations. Conversion: SI to traditional units-Sodium: 1 mmol/l=1 mEq/l. Angiotensin II: 1 pmol/l 1 pg/ml. Aldosterone: 1 pmol/l 36 pg/100 ml.
Captopril induced a well-defined fall in plasma sodium concentration, which reached a nadir 7 mmol/I below baseline values on the third and fourth days oftreatment (figure). Plasma concentrations ofangiotensin IV and aldosterone2 declined in parallel with those of sodium (figure), and for all data (n = 70) significant relations between plasma concentrations of angiotensin II and sodium (r=0-43, p<0.001) and between concentrations of aldosterone and sodium (r=0-37, p<0.001) were observed. In contrast to the decline in plasma sodium, angiotensin II, and aldosterone concentrations, plasma renin activity increased appreciably. For all data (n = 70) there was a significant reciprocal relation between plasma renin activity and concurrent plasma sodium concentrations (r= -0 53, p <0 001). Plasma potassium concentrations also rose, from a mean (± SEM) of 3-55 +0-16 mmol/l before treatment to 4-40 ± 0-13 mmol/l on the fifth day of treatment.
Treatment with captopril did not alter cumulative sodium balance or body weight (figure). Haemodynamic improvement occurred in all patients during treatment, and no symptoms attributable to hyponatraemia were observed.
Comment
We found that plasma sodium concentration fell when captopril was used to treat resistant heart failure. A parallel decline in circulating concentrations of angiotensin II and aldosterone and reciprocal increments in plasma renin activity and plasma potassium concentrations were noted. It is tempting to relate the fall in plasma sodium and the rise in plasma potassium concentrations to the decrease in aldosterone concentrations, since similar though less pronounced electrolyte changes are seen during treatment with spironolactone in congestive heart failure.3 Interestingly, frank hyponatraemia is not often observed in the syndrome of hyporeninaemic hypoaldosteronism unless there is coincidental sodium restriction or volume depletion.4 Since angiotensin II can stimulate thirst, release of antidiuretic hormone, and water retention by the kidneys,5 a fall in angiotensin II taken alone might be expected to result in a rise rather than a fall in plasma sodium concentration. Whatever the mechanisms entailed, plasma sodium as well as potassium concentrations should be monitored during captopril treatment in cardiac failure.
3 Nicholls MG, Espiner EA, Hughes H, Rogers T. Effect of potassiumsparing diuretics on the renin-angiotensin-aldosterone system and potassium retention in heart failure. Br Heart), 1976;38:1025-30. There has recently been considerable speculation whether microaerophilic' and anaerobic bacteria2 cause urinary tract infections. We describe a patient who repeatedly had "sterile pyuria" whom we found to be suffering from repeated infections caused by microaerophilic and anaerobic organisms.
Case report
A 76-year-old fit-looking and active woman with a 13-year history of urinary tract infection caused by Escherichia coli and Proteus spp first attended our clinic in October 1978. An ileocystoplasty had been carried out in May 1966 to increase her bladder capacity. Her non-functioning right kidney (extensively calcified and containing a large staghorn calculus) had been removed in January 1972. We found raised serum urea (15-7 mmol/l
